EMA approval was granted after extensive phase III trials which indicated the drug extended the life of men suffering from a type of prostate cancer considerably. It also slowed the time it took the cancer to progress compared to standard chemotherapy drugs.
However, Sanofi will face competition from US firm Dendreon, as they seek to launch their drug Provenge into the European market. Ultimately, Provenge extends the patient’s life further and reduces the risk of death by nearly 25%, though it would cost £25,000 more to treat a single patient than Jevtana, so would struggle to be able to convince NICE that it is worth the extra cost.
Looking for a job in science? Start by looking here, now